1. Home
  2. Companies
  3. LTP
  4. Material Events

Ltr Pharma (ASX:LTP) — Material Events

ASX:LTP · 20 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 18 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
18
LTR Pharma Accelerates Market Reach with SPONTAN’s Breakthrough Absorption SpeedMedium
LTR Pharma posts strong FY25 progress with rapid-acting SPONTAN, new partnerships, and expanded portfolio
29 Aug 2025 ·Full-Year Results ·85
LTR Pharma Hits 1,000 SPONTAN Prescriptions, Eyes US Launch in H1 2026Medium
LTR Pharma advances clinical trials and US launch plans with strong cash position
28 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·85
LTR Pharma Launches SPONTAN Nationwide, Eyes US ROXUS Debut in 2026Medium
LTR Pharma advances nasal spray pipeline with SPONTAN launch, ROXUS US market prep, and new OROFLOW program
29 July 2025 ·Quarterly Activities Report & Appendix 4C ·85
LTR Pharma Locks in US Telehealth Deal with 150,000-Unit ROXUS TargetMedium
LTR Pharma signs binding U.S. telehealth deal with Shed Holdings for ROXUS commercialisation
9 June 2026 ·Commercialisation Agreement ·85
LTR Pharma Accelerates Intranasal ED Innovation with Strategic Partnerships and Market ExpansionMedium
LTR Pharma advances intranasal ED treatments, expands partnerships, reports FY25 loss of A$5.59M
29 Aug 2025 ·Annual Report ·85
LTR Pharma Validates 5x Faster ED Relief with SPONTAN in Peer-Reviewed StudyMedium
LTR Pharma's SPONTAN shows 5x faster onset than oral ED tablets in peer-reviewed study
20 Aug 2025 ·Clinical Data Publication ·85
LTR Pharma Advances Rapid-Onset Intranasal ED Therapy SPONTAN with Strong Clinical DataMedium
LTR Pharma advances rapid-onset intranasal ED therapy SPONTAN with strong clinical data, strategic partnerships, and $24.1M cash
1 May 2026 ·Investor Update ·85
LTR Pharma Accelerates US Launch with New Advisory Board and Clinical ValidationMedium
LTR Pharma advances ROXUS US launch, strengthens advisory board, and expands omega-3 portfolio with strong cash position
29 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
LTR Pharma Secures Exclusive US Pharmacy Partner to Boost ROXUS LaunchMedium
LTR Pharma secures exclusive US pharmacy partner for ROXUS® ahead of commercial launch
11 June 2026 ·Partnership Agreement Announcement ·80
LTR Pharma’s SPONTAN Hits 18-Month Shelf Life, Poised for Global ExpansionMedium
LTR Pharma's SPONTAN achieves 18-month shelf life, boosting global commercial prospects
22 Aug 2025 ·Product Update ·80
LTR Pharma’s OROFLOW® Gains Ethics Nod to Target $8 Billion Oesophageal Motility MarketMedium
LTR Pharma's OROFLOW® Intranasal Spray Approved for Clinical Study in Oesophageal Motility Disorders
24 June 2026 ·Clinical Study Announcement ·75
LTR Pharma Advances SPONTAN Trial with Ethics Nod for Older Men StudyMedium
LTR Pharma secures ethics approval for SPONTAN Phase II clinical trial targeting older men
3 Dec 2025 ·Clinical Trial Announcement ·75
LTR Pharma Completes Phase II Recruitment for SPONTAN, Data Due Q2 2026Medium
LTR Pharma completes Phase II recruitment for SPONTAN ED treatment, data expected Q2 2026
5 Mar 2026 ·Clinical Trial Update ·75
LTR Pharma Secures 33% Stake in LevOmega to Tap Into Pharma-Grade Omega-3 MarketMedium
LTR Pharma acquires 33% stake in LevOmega to enter pharmaceutical-grade omega-3 market
22 Sept 2025 ·Equity Investment Announcement ·75
LTR Pharma Doses First Patients in Pivotal SPONTAN Phase II StudyMedium
LTR Pharma initiates Phase II dosing for SPONTAN erectile dysfunction spray
22 Jan 2026 ·Clinical Trial Update ·75
LTR Pharma Completes SPONTAN Phase II Recruitment; Interim Data Due Q2 2026Medium
LTR Pharma completes SPONTAN Phase II recruitment; interim data due Q2 2026; ROXUS US commercial talks progress
28 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·75
LTR Pharma’s SPONTAN Wins 100% Patient Satisfaction Post-ProstatectomyMedium
LTR Pharma's SPONTAN achieves 100% patient satisfaction in post-prostatectomy ED case series
25 Aug 2025 ·Clinical Update ·75
LTR Pharma Affirms Timely Disclosure of US ROXUS Deal Amid ASX Trading InquiryMedium
LTR Pharma confirms timely disclosure of binding US ROXUS agreement following ASX query
15 June 2026 ·ASX Query Response ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.